auch intressant

P. Vincent Mehdizadeh founded Medbox's main subsidiary, Medicine Dispensing Systems, in February 2008. He commenced operations for that company in 2010, and in December of 2011 sold that company to what became Medbox, Inc. Mr. Mehdizadeh served as senior consultant from December 2012 until May 10, 2013 for Medbox, Inc. and then transitioned to Chief Operations Officer and Board Chairman for Medbox, Inc. through May of 2014. Mr. Mehdizadeh was responsible for creating the 2 main patents behind the company's technology, helping to assemble the talented management team at Medbox, and also developing the concept behind the business models driving revenue for the company.

Media Contact:
Innovation Agency
310-571-5592

The transaction has 6 separate closings over the course of 18 months, with each of the first 5 closings being in the amount of $2 million dollars to be paid to Mehdizadeh's holding company and Medbox equally, to satisfy the $5 million dollar direct investment component of the transaction. The 6 and final closing has a performance contingency and is in the amount of $5 million dollars paid directly to Mehdizadeh's holding company.

A representative of Lizada will join Medbox's board of directors within the next 90 days, after the first closing is set to occur.

A spokesman for Lizada Capital LLC noted, "We see incredible opportunity for growth at Medbox and look forward to working with our fellow board members to realize all of the possibilities that exist for this already well-established legal cannabis enterprise."

Mehdizadeh further commented, "I look forward to developing assets within the cannabis sector, outside of Medbox, with the hope to someday bring those assets to Medbox for consideration as potential acquisition targets. My loyalty, allegiance, and consulting talent will always have precedence for Medbox and I will make myself available to the board and management team in perpetuity."

About P. Vincent Mehdizadeh, Founder and Majority Shareholder at Medbox, Inc.

P. Vincent Mehdizadeh founded Medbox's main subsidiary, Medicine Dispensing Systems, in February 2008. He commenced operations for that company in 2010, and in December of 2011 sold that company to what became Medbox, Inc. Mr. Mehdizadeh served as senior consultant from December 2012 until May 10, 2013 for Medbox, Inc. and then transitioned to Chief Operations Officer and Board Chairman for Medbox, Inc. through May of 2014. Mr. Mehdizadeh was responsible for creating the two main patents behind the company's technology, helping to assemble the talented board/management team at Medbox, and also developing the concept behind the business models driving revenue for the company. Mr. Mehdizadeh was responsible for funding and the creation of the Marijuana Policy Project "Consume Responsibly" campaign, as well as the Americans For Safe Access "Medicate Responsibly" campaign. Mehdizadeh has donated over $2 million dollars to Americans for Safe Access (ASA), Marijuana Policy Project (MPP), Drug Policy Alliance (DPA), Law Enforcement Against Prohibition (LEAP), and St. Jude Children's Research Hospital.

About Lizada Capital LLC:

Lizada is a privately held entity formed in 2004 for the principal purpose of investing in emerging market opportunities. In 2013, following a two-year period of industry evaluation, the company started primarily focusing on the cannabis industry, Since then, Lizada has invested in public companies including GW Pharmaceuticals, AmeriCann and CannLabs and private companies, CDX, MJIC, Panther Capital, New Frontier, Noble Blends, Medicine Man Technologies, Las Vegas CannaPlex and Quigley's.  

MedBox Inc (OTCMKTS: MDBX) angepasst Berichte zeigten, dass die Aktionäre haben allen Grund, über das Unternehmen aufgeregt zu werden. Die ausgewiesenen Unterschiede sind riesig und wandelt die positive Umsatz in negative Einnahmen. Gemäß den ursprünglichen 1Q2014 Zahlen betrug der Umsatz $ 331.000 während jetzt nach angepassten Ergebnissen steht bei negativen $ 8,000. Der Umsatz für GJ 2012 im ursprünglichen Bericht war $ 2.590.000, die bei $ 1.170.000 in restated Einreichung kam. Die Einnahmen für FY2013 im ursprünglichen Bericht war $ 5.220.000, die nun das Unternehmen berichtet, bei $ 2.060.000 in restated Anmeldung.

Der Abschluss

Nichts mehr zu sagen, MedBox abgesehen von einem einzigen Wort, und das ist "Vorsicht". Die angepassten Zahlen erschüttert die Aktionäre Vertrauen in das Unternehmen. Die Auswirkungen der angepassten Zahlen weiter auf MDBX die Aktienkurse in den kommenden Tagen zu sehen.